Home » Stocks » KZR

Kezar Life Sciences, Inc. (KZR)

Stock Price: $5.15 USD 0.22 (4.46%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $5.10 -0.05 (-0.95%) May 13, 4:11 PM
Market Cap 247.61M
Revenue (ttm) n/a
Net Income (ttm) -41.74M
Shares Out 44.00M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $5.15
Previous Close $4.93
Change ($) 0.22
Change (%) 4.46%
Day's Open 5.02
Day's Range 4.94 - 5.23
Day's Volume 139,133
52-Week Range 4.24 - 9.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

1 day ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

3 days ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncolo...

1 month ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and on...

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and on...

3 months ago - Business Wire

Kezar is a founder-driven company with deep expertise in proteasome and drug development, and they have a track record of approved medicines. The company's lead asset, KZR-616, is a first-in-class inhib...

3 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and on...

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

4 months ago - Business Wire

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic...

6 months ago - Business Wire

Kezar is a young company with two candidates in clinical development. Development programs with broad therapeutic potential.

6 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and o...

6 months ago - Business Wire

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disor...

6 months ago - Business Wire

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disor...

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.

7 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.

8 months ago - Business Wire

Kezar Life Sciences: Exploring New Options For Autoimmune Diseases

8 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.

8 months ago - Business Wire

Kezar Life Sciences, Inc. (KZR) CEO John Fowler on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disor...

9 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.

9 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc.

9 months ago - Business Wire

The company's public offering of common stock doesn't exactly thrill investors.

11 months ago - The Motley Fool

Kezar Life Sciences just released interim results on its only drug and shares jumped 70%. Now that the stock has settled, is it a good time to buy?

11 months ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therape...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therape...

11 months ago - GlobeNewsWire

Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: ABBV, ALDX
11 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therape...

11 months ago - GlobeNewsWire

Kezar Life Sciences (KZR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 11th

Other stocks mentioned: BGS, NERV, W
1 year ago - Zacks Investment Research

Kezar Life Sciences: Key Catalysts Ahead

1 year ago - Seeking Alpha

SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat un...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeu...

1 year ago - GlobeNewsWire

Is (KZR) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeut...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeut...

1 year ago - GlobeNewsWire

Wall Street sell-side analysts recommend buying shares of Aurora Mobile Limited (NASDAQ:JG) and Kezar Life Sciences Inc (NASDAQ:KZR), two falling knives whose share prices lost more than 59% over the pa...

Other stocks mentioned: JG
1 year ago - GuruFocus

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therape...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeut...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therape...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therape...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeu...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeut...

1 year ago - GlobeNewsWire

Shares of Kezar Life Sciences Inc (NASDAQ: KZR) have retreated to a fresh 52-week low on roughly five times their average volume.

1 year ago - Benzinga

Kezar Life Sciences Inc. shares were absolutely crushed on Tuesday after the firm revealed data from its midstage trial in patients with systemic lupus erythematosus (SLE).

1 year ago - 24/7 Wall Street

About KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products includ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 21, 2018
CEO
John Fowler
Employees
47
Stock Exchange
NASDAQ
Ticker Symbol
KZR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for KZR stock is "Strong Buy." The 12-month stock price forecast is 15.00, which is an increase of 191.26% from the latest price.

Price Target
$15.00
(191.26% upside)
Analyst Consensus: Strong Buy